

ONCOSEC MEDICAL Inc  
Form 8-K  
August 08, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **August 2, 2013**

**ONCOSEC MEDICAL INCORPORATED**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**000-54318**  
(Commission  
File Number)

**98-0573252**  
(I.R.S. Employer  
Identification No.)

**9810 Summers Ridge Road**  
**San Diego, California**

(Address of principal executive offices)

**92121**  
(Zip Code)

Registrant's telephone number, including area code: **(855) 662-6732**

**Not Applicable**

(Former name or former address, if changed since last report.)

## Edgar Filing: ONCOSEC MEDICAL Inc - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02** **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(e)

On August 2, 2013, the Compensation Committee (the *Committee*) of the Board of Directors of OncoSec Medical Incorporated ( *OncoSec* ) approved an amendment (the *Amendment* ) to that certain employment agreement, dated as of May 18, 2011, by and between OncoSec and Veronica Vallejo, OncoSec's Chief Financial Officer, (the *Employment Agreement* ). Pursuant to the Amendment, (i) the severance payment payable to Ms. Vallejo in the event of her termination is to equal twelve (12) months (the *Severance Period* ) of her annual salary at the time of termination and (ii) the period for which the Company will pay for applicable premium costs for continued group health plan coverage was increased to the Severance Period, subject in each case to the terms of the Employment Agreement. Prior to the Amendment, the Employment Agreement provided for a Severance Period of six (6) months. A copy of the Amendment is attached as Exhibit 10.1 to this Current Report on Form 8-K.

**Item 9.01** **Financial Statements and Exhibits.**

(d) *Exhibits.*

<b>Exhibit No.</b>	<b>Description</b>
10.1	Amendment No. 1 to Employment Agreement, by and between OncoSec Medical Incorporated and Veronica Vallejo, dated as of August 2, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ONCOSEC MEDICAL INCORPORATED**

Dated: August 8, 2013

By: */s/ Punit Dhillon*  
Punit Dhillon  
*President and Chief Executive Officer*  
*(Principal Executive Officer)*

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
10.1	Amendment No. 1 to Employment Agreement, by and between OncoSec Medical Incorporated and Veronica Vallejo, dated as of August 2, 2013